ATS: SB010 Cuts Early, Late Response in Allergic Asthma

This article originally appeared here.
Share this content:
ATS: SB010 Cuts Early, Late Response in Allergic Asthma
ATS: SB010 Cuts Early, Late Response in Allergic Asthma

(HealthDay News) -- For patients with allergic asthma, a novel DNA enzyme that is able to cleave and inactivate GATA3 mRNA, SB010, attenuates early and late asthmatic responses, according to a study published online May 17 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Thoracic Society, held from May 15 to 20 in Denver.

Norbert Krug, M.D., from Hannover Medical School in Germany, and colleagues conducted a randomized trial involving patients with allergic asthma with sputum eosinophilia and who had biphasic early and late asthmatic responses after laboratory-based allergen provocation. A group of 40 patients were randomized to receive 10 mg of SB010 (21 patients) or placebo (19 patients) administered by inhalation once daily for 28 days.

The researchers found that SB010 correlated with a 34 percent reduction in the mean late asthmatic response, compared with the baseline response, based on the area under the curve for forced expiratory volume in one second (FEV1), while there was a 1 percent increase in the AUC for FEV1 with placebo (P = 0.02). The early asthmatic response was attenuated by 11 percent with SB010 and increased by 10 percent with placebo (P = 0.03).

"Treatment with SB010 significantly attenuated both late and early asthmatic responses after allergen provocation in patients with allergic asthma," the authors write.

The study was funded by Sterna Biologicals.

Abstract
Full Text
Editorial
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths